Summit Therapeutics Inc. develops oncology medicines led by ivonescimab, an investigational PD-1 / VEGF bispecific antibody in-licensed from Akeso. The company reports clinical and operational updates for ivonescimab programs in non-small cell lung cancer and colorectal cancer, including multiregional Phase III studies and data presentations from HARMONi trials.
Recurring Summit Therapeutics news also covers financial results, regulatory updates tied to the accepted Biologics License Application for ivonescimab in EGFR-mutated non-squamous NSCLC after tyrosine kinase inhibitor therapy, clinical trial collaborations, and equity-compensation actions under Nasdaq rules. Summit holds development and commercialization rights for ivonescimab across North America, South America, Europe, the Middle East, Africa, and Japan.
Summit Therapeutics (NASDAQ: SMMT) reported significant progress in Q3 2024, highlighted by their lead drug ivonescimab achieving a 49% reduction in disease progression or death compared to pembrolizumab in first-line PD-L1 positive advanced NSCLC. The company completed enrollment in the global Phase III HARMONi trial, received FDA Fast Track Designation, and plans to expand the HARMONi-3 trial to include non-squamous histology patients. Summit raised $235 million in private financing, ending Q3 with $487 million in cash. Financial results showed GAAP net loss of $56.3 million ($0.08 per share) and increased R&D expenses to $37.7 million, reflecting expanded clinical development activities.
Nuvectis Pharma (NASDAQ: NVCT) showcased promising results at the AACR-NCI-EORTC Symposium, where its drug candidate NXP900 demonstrated strong synergy with ALK inhibitors in resistant non-small cell lung cancer (NSCLC) cells. The drug effectively targets SRC/YES1 kinases, addressing resistance mechanisms in cancer treatment.
The company is also anticipating data updates from NXP800's Phase 1b study in platinum-resistant, ARID1a-mutated ovarian cancer. With a current market valuation of approximately $150 million, Nuvectis is positioning itself alongside industry players like Summit Therapeutics ($15B) and Nuvalent ($6.6B) in the precision oncology space.
Summit Therapeutics (NASDAQ: SMMT) has announced it will host an earnings conference call on Wednesday, October 30, 2024, before market opening. The call, scheduled for 9:00am ET, will cover the company's third quarter 2024 financial results and provide an operational update. The event will be accessible through a live webcast on Summit's website, with an archived version available afterward.
Summit Therapeutics (NASDAQ: SMMT) has granted inducement awards of stock options to ten new employees. The collective total of options allows for the purchase of up to 249,550 shares of common stock. These awards were granted on October 1, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4) and approved by the Company's Compensation Committee.
The options have a ten-year term and an exercise price of $20.10 per share, matching the closing price of Summit's common stock on October 1, 2024. The options will vest in equal annual installments over four years and are subject to the terms of a stock option agreement to be executed by the recipients.
Summit Therapeutics (NASDAQ: SMMT) has completed enrollment for its HARMONi Phase III clinical trial, evaluating ivonescimab plus platinum-doublet chemotherapy in EGFR-mutated NSCLC patients who progressed after 3rd generation EGFR TKI treatment. The study enrolled patients from North America, Europe, and China. Additionally, the FDA has granted Fast Track designation for ivonescimab in this indication, potentially expediting its development and review process.
The HARMONi trial's topline data is expected in mid-2025. The study's analysis will include patients from the HARMONi-A trial, which led to marketing authorization in China for ivonescimab on May 24, 2024. HARMONi is designed with dual primary endpoints of progression-free survival and overall survival.
Nuvectis Pharma's NXP900 is emerging as a promising candidate in the fight against Non-Small Cell Lung Cancer (NSCLC), particularly for patients resistant to EGFR and ALK targeted therapies. Like Summit Therapeutics' Ivonescimab, which recently outperformed Merck's Keytruda in a Phase 3 trial, NXP900 targets treatment resistance but through a different mechanism.
NXP900 inhibits SRC/YES1 kinases, key drivers of cancer survival. Preclinical studies show its potential to reverse resistance to existing therapies and enhance their effectiveness when used in combination. While still in early clinical development, NXP900's targeted approach and potential applications beyond NSCLC make it a noteworthy contender in the evolving landscape of cancer treatment.
Summit Therapeutics (NASDAQ: SMMT) presented promising data for ivonescimab, a novel bispecific antibody, at ESMO 2024. Phase II studies showed encouraging results in colorectal cancer (CRC), triple-negative breast cancer (TNBC), and head and neck squamous cell carcinoma (HNSCC).
In CRC, ivonescimab plus chemotherapy achieved an 81.8% overall response rate and 100% disease control rate. For TNBC, the combination showed a 72.4% overall response rate and 9.3-month median progression-free survival. In HNSCC, ivonescimab alone or with ligufalimab demonstrated response rates of 30% and 60%, respectively.
These results support Summit's plans to expand ivonescimab's clinical development beyond non-small cell lung cancer. The drug's safety profile was generally manageable across all studies.
Summit Therapeutics (NASDAQ: SMMT) has successfully raised $235 million through a private placement of approximately 10.35 million shares at $22.70 per share. The fundraise was led by insiders and prominent biopharma institutional investors, with $79 million coming from company insiders and $156 million from external investors. Notably, all of Summit's Section 16 officers participated in the capital raise.
The company plans to use the proceeds to advance the clinical development of ivonescimab, focusing on non-small cell lung cancer and potentially expanding into colorectal cancer and triple-negative breast cancer. The capital raise was completed without bankers' fees, maximizing the net proceeds for Summit's research and development efforts.
Summit Therapeutics (NASDAQ: SMMT) announced positive results from the Phase III HARMONi-2 trial of ivonescimab, a novel bispecific antibody, in first-line treatment of PD-L1 positive advanced NSCLC. The trial showed:
- 49% reduction in risk of disease progression or death compared to pembrolizumab
- Median PFS of 11.14 months vs 5.82 months for pembrolizumab
- Benefits across subgroups, including PD-L1 high and low expression
- Comparable safety profile to pembrolizumab
Summit plans to initiate HARMONi-7, a Phase III trial in first-line PD-L1 high advanced NSCLC, in early 2025. Additional Phase II data in other solid tumors will be presented at ESMO 2024.
Summit Therapeutics (NASDAQ: SMMT) has granted inducement awards to five new employees, consisting of options to purchase up to 102,000 shares of common stock. These awards, approved by the Company's Compensation Committee, were made in accordance with Nasdaq Listing Rule 5635(c)(4). The options, granted on September 4, 2024, have a ten-year term and an exercise price of $12.00 per share, matching the closing price of Summit's common stock on that date. The options will vest in equal annual installments over four years and are subject to the terms of a stock option agreement.